Vertex Pharma (VRTX) Offering Possible 31.58% Return Over the Next 23 Calendar Days

Vertex Pharma’s most recent trend suggests a bullish bias. One trading opportunity on Vertex Pharma is a Bull Put Spread using a strike $200.00 short put and a strike $190.00 long put offers a potential 31.58% return on risk over the next 23 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $200.00 by expiration. The full premium credit of $2.40 would be kept by the premium seller. The risk of $7.60 would be incurred if the stock dropped below the $190.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Vertex Pharma is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Vertex Pharma is bullish.

The RSI indicator is at 35.34 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Vertex Pharma

Forget Bitcoin: 4 Stocks to Buy Hand Over Fist Instead
Sun, 21 Feb 2021 11:36:00 +0000
Since the March 23 bear market low, the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite are up a cool 70%, 76%, and 104%, respectively. Many of the same theses that bulls have extolled for years continue to drive Bitcoin’s ascent. For example, fans still view its 21 million token limit as a hedge against the long-term devaluation of the U.S. dollar as the money supply increases.

What Should Vertex Pharmaceuticals Buy With its $6.6 Billion Stash?
Sat, 20 Feb 2021 12:10:00 +0000
Vertex Pharmaceuticals (NASDAQ: VRTX) has $6.6 billion in the bank and continues to generate more cash flow each quarter. While Vertex has some early stage drugs that could generate revenue in a few years, the company is also looking to buy growth through the acquisition of a late-stage pipeline candidate or two (or three). In this video from Motley Fool Live recorded on Feb. 8, Fool.com contributors Brian Orelli and Keith Speights discuss the biotech’s pipeline and where it might expand beyond cystic fibrosis.

Here’s Why Vertex Pharmaceuticals’ Fourth Quarter Was Better Than It First Appeared
Fri, 19 Feb 2021 12:50:00 +0000
The duo also discuss the difference between the launch of Tikafta in the U.S. and the rollout of the drug in Europe, where it goes by the name Kaftrio. Brian Orelli: First up, Vertex Pharmaceuticals earnings, this is a cystic fibrosis specialist. Revenue was up only 15% year-over-year, but that’s a little misleading because the year-ago-quarter, that fourth-quarter of 2019, had about $155.8 million associated with sales of Orkambi in France.

Is Vertex Pharmaceuticals (VRTX) Stock a Buy For 2021?
Thu, 18 Feb 2021 17:49:01 +0000
Baron Health Care Fund recently published its fourth-quarter commentary – a copy of which can be downloaded here. During the fourth quarter of 2020, the Baron Health Care Fund returned 17.1% (institutional shares). In comparison, the benchmark S&P 500 Index was up 12.15%, while the Russell 3000 Health Care Index was up 10.08%. You should […]

Here’s What Caused Royalty Pharma’s Mixed Results in Q4
Wed, 17 Feb 2021 19:00:00 +0000
Most investors would view Royalty Pharma (NASDAQ: RPRX) as a disappointment. Royalty Pharma announced its fourth-quarter results before the market opened on Wednesday. Here are the highlights from Royalty Pharma’s Q4 results.

Be Sociable, Share!

Related Posts